Senior Respiratory Pharmacist, Glenfield Hospital, Leicester
The UK is experiencing an explosion of new drugs and inhaler devices being licensed for people with respiratory disease, increasing the complexity of prescribing for people with asthma or chronic obstructive pulmonary disease (COPD). The management of how these new products are introduced into clinical practice is important because they may vary in type of inhaler device and licensing. One product is DuoRespSpiromax, a cheaper “branded generic” of Symbicort Turbohaler, both containing
Primum non nocereSubscription
We welcome the comments from Stuart Hill providing a counter-argument to the concerns initially raised by the UK Clinical Pharmacy Association Respiratory Group about Relvar Ellipta.